Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples